Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com.
To see our community guidelines, please visit: bit.ly/2l0yiI3
Company Details
- Employees
- 1.56K
- Founded
- -
- Address
- Yeonsu-Gu, Incheon 21987, Kr
- Phone
- +82 - 32 - 455 - 6114
- bi****@****ung.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- samsungbioepis.com
- Keywords
- biosimilars, pharmaceutical, biopharmaceutical, biotechnology, regulatory affairs, clinical trials, research and development, oncology, immunology, ophthalmology, science, quality, innovation, healthcare.
- HQ
- Yeonsu-gu, Incheon
Samsung Bioepis Questions
Samsung Bioepis's helpline number is +82 - 32 - 455 - 6114
Samsung Bioepis's website is samsungbioepis.com
Samsung Bioepis's LinkedIn profile is https://kr.linkedin.com/company/samsungbioepis
Samsung Bioepis has
1.56K employees.
View email and phone details for 1.56K
employees at Samsung Bioepis.
Samsung Bioepis's industry is
Pharmaceutical Manufacturing
Samsung Bioepis's top competitors are
Lotte Biologics,
Daewoong Pharmaceutical,
Pfizer,
Gc Biopharma (Gc녹십자),
Lg Chem,
Samsung Biologics,
Celltrion Inc,
Gsk,
Sk Bioscience,
Sk Biopharmaceuticals.
Samsung Bioepis's support email address is bioepisinfo@samsung.com
Samsung Bioepis's categories are Pharmaceutical Manufacturing
Samsung Bioepis's founding year is 2012
